Excision BioTherapeutics Appoints Christine Silverstein as Chief Financial Officer

Excision BioTherapeutics (“Excision”) appointed Christine Silverstein as Chief Financial Officer. Christine joins Excision with more than 15 years of financial leadership and capital markets expertise in the biopharmaceutical industry. Most recently, she served as Chief Financial Officer of Emendo Biotherapeutics.
 
Excision Biotherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. It is based in Philadelphia, PA, and employs approximately 22 people.